Iovance Biotherapeutics

Iovance Biotherapeutics is a leading brand that is revolutionizing cancer treatment through its pioneering approach. Their mission is to develop and deliver tumor infiltrating lymphocyte (TIL) therapy, leveraging the power of the human immune system to recognize and attack cancer cells in each patient. With their late-stage TIL product candidate, lifileucel, they aim to create the first approved one-time cell therapy for solid tumor cancer, specifically metastatic melanoma. Iovance's TIL platform has shown promising results in clinical trials for various solid tumors. The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, providing hope for cancer patients. As a patient-centric and collaborative organization, Iovance values integrity, agility, innovation, collaboration, and excellence in everything they do. Their dedicated and experienced management team is at the forefront of this ground-breaking work. Please note that TIL therapy is still investigational and has not been approved by the FDA or any other regulatory agency.